Candel Therapeutics, Inc.

NASDAQ•CADL

執行長: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-07-27

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

聯絡資訊

117 Kendrick Street, Suite 450, Needham, MA, 02494, United States

617-916-5445

www.candeltx.com

市值

$267.37M

本益比 (TTM)

-7.0

股息率

52周最高

$7.25

52周最低

$4.34

52周範圍

18%

排名58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 2.3 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q4 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.54+0.00%

近4季度走勢

自由現金流

-$10.98M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Net Loss Narrows Significantly Net loss decreased $16,995 K to $(38,182) K for 2025, reflecting reduced warrant liability impact.

Aglatimagene Prostate Success Phase 3 DFS endpoint met for aglatimagene plus radiation (HR 0.70); median DFS not reached.

R&D Investment Increases Research and development expenses increased $11.18M to $30.50M, driven by clinical trial manufacturing costs.

Cash Position Strengthened Cash and equivalents totaled $119.73M by year-end 2025, supported by recent financing activities.

關注風險

Substantial Funding Required Need substantial additional funding; inability to raise capital forces program delays, reductions, or cessation of operations.

No Product Sales Revenue Limited operating history; no revenue generated from product sales; expecting continued operating losses for foreseeable future.

Clinical Trial Success Dependency Business success depends on clinical trials adequately demonstrating safety and efficacy for aglatimagene and linoserpaturev.

Unpredictable Regulatory Approval Regulatory approval processes are lengthy, complex, and inherently unpredictable, potentially impairing revenue generation.

未來展望

Prostate BLA Submission Planned Ongoing dialogue with FDA for aglatimagene BLA submission in prostate cancer targeted for fourth quarter of 2026.

NSCLC Phase 3 Trial Launch Plan to initiate pivotal phase 3 trial for metastatic NSCLC patients resistant to ICI treatment in second quarter of 2026.

Cash Runway Extended Existing cash plus 2026 Follow-On Offering proceeds expected to fund operations into the first quarter of 2028.

Biomarker Data Presentation Expect to present novel immunological biomarker data in localized prostate cancer patients during third quarter of 2026.

同行對比

營業收入 (TTM)

EDIT

$40.52M

+25.4%

PRQR

$17.94M

-15.9%

IMMP

$8.35M

+121.2%

毛利率 (最新季度)

EDIT

100.0%

+2621.3pp

ACIU

100.0%

+0.0pp

PRQR

85.5%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
CAPR	$1.58B	-16.1	-67.5%	5.9%
DRTS	$672.39M	-15.4	-57.3%	12.9%
CTNM	$476.41M	-6.6	-30.1%	3.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月7日

每股收益:-$0.31

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料